Rapid Micro Biosystems, Inc. (RPID) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call revealed positive signs such as a guidance raise due to a large multi-system order, consistent global demand, and improved service margins. Despite a net loss, operating expenses decreased, and cash reserves are strong. The MilliporeSigma partnership and high ROI investments further bolster the outlook. However, management's lack of clarity on some order specifics and onshoring timelines tempers enthusiasm. Overall, the positive factors outweigh the negatives, suggesting a stock price increase in the near term.
Key Financial Performance
Total third quarter revenue $7.8 million, a 3% increase compared to $7.6 million in Q3 2024. The increase was driven by record consumable revenue offsetting the impact of 2 fewer system placements compared to Q3 2024.
Product revenue $5.2 million, essentially flat compared to Q3 2024. Record consumable revenue offset the impact of 2 fewer system placements.
Service revenue $2.6 million, a 12% increase compared to Q3 2024, driven by higher service contract revenue resulting from an increase in the cumulative number of validated systems.
Recurring revenue $4.8 million, a 32% increase year-over-year, with consumables growing 40% in the period.
Nonrecurring revenue $3 million, primarily comprised of systems and validation revenue.
Third quarter gross margin 9%, marking a 70 basis point improvement from the prior year quarter and a sequential improvement of over 500 basis points compared to Q2. Higher revenue and productivity gains drove service margins to 40%.
Product margins Negative 7% in Q3 2025 compared to negative 1% in Q3 2024. Consumable margins improved meaningfully, but overall product margins were slightly lower due to a short-term shift in the mix of revenue from systems to consumables.
Service margins 40% in Q3 2025 compared to 29% in Q3 2024, driven by higher revenue, productivity, and lower service headcount.
Operating expenses $12.1 million in Q3 2025, a 5% decrease from $12.7 million in Q3 2024, due to benefits from the operational efficiency program.
Net loss $11.5 million in Q3 2025 compared to $11.3 million in Q3 2024. Net loss per share remained at $0.26 for both periods.
Cash and investments Approximately $42 million at the end of Q3 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Growth Direct System: Secured a record multi-system order from a top 20 global biopharma customer, deploying systems across North America, Europe, and Asia Pacific. The system will be used for environmental monitoring, water, and bioburden applications. This highlights the platform's position as a leading automated solution for biopharmaceutical manufacturing.
Consumables: Achieved a 40% increase in consumable revenue, setting a quarterly record. This indicates strong customer demand and usage.
MilliporeSigma Partnership: Collaboration progressing well, with MilliporeSigma beginning to order Growth Direct Systems. The partnership is expected to contribute meaningfully to system placements in 2026.
Global Expansion: The company is expanding its global installed base, now at 174 cumulative systems placed, including 152 fully validated systems. The recent multi-system order will further expand presence in North America, Europe, and Asia Pacific.
Gross Margins: Achieved a 9% gross margin in Q3, marking the fifth consecutive quarter of positive gross margins. Service margins improved to 40%, driven by higher revenue and productivity gains.
Operational Efficiency: Reduced operating expenses by 5% year-over-year, reflecting benefits from an operational efficiency program initiated in August last year.
Revenue Guidance: Raised full-year 2025 revenue guidance to at least $33 million, driven by strong year-to-date performance and contributions from the recent multi-system order.
Automation and Onshoring Trends: Positioned to capitalize on industry trends like increased automation and onshoring of U.S. pharmaceutical manufacturing, leveraging the Growth Direct platform's value proposition.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue and Margin Challenges: Product margins were slightly negative in Q3 2025, and while improvements are expected, the company faces challenges in achieving positive product margins consistently. Service margins are also expected to step down in Q4 due to timing of validation activities.
Customer Order Variability: Consumable revenue is expected to decline sequentially in Q4 due to variability in the timing of customer orders and shipments, which could impact revenue predictability.
Operational Efficiency: While operational efficiency programs have reduced expenses, the company still reported a net loss of $11.5 million in Q3 2025, indicating ongoing financial strain.
Dependence on Key Partnerships: The company’s collaboration with MilliporeSigma is critical for future growth and margin improvement, but the financial benefits are not expected until the second half of 2026, creating a dependency on successful execution of this partnership.
Macroeconomic and Market Conditions: The company acknowledges potential adverse impacts from general macroeconomic conditions on its business and that of its customers, which could affect future performance.
Debt and Financial Obligations: The company’s ability to access future tranches under its debt facility and comply with obligations is a risk factor that could impact operational flexibility.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2025: The company has raised its full-year 2025 revenue guidance to at least $33 million, which includes at least 27 Growth Direct System placements.
Revenue Growth Drivers for 2026: Three core drivers of revenue growth in 2026 include: a robust sales pipeline with multiple customers planning multi-system global rollouts, an expanding global installed base of over 150 validated Growth Direct Systems generating recurring revenue, and contributions from the MilliporeSigma collaboration.
Gross Margin Improvement: Gross margins are expected to improve meaningfully in 2026, driven by product cost reductions, manufacturing efficiency initiatives, and benefits from the MilliporeSigma supply collaboration.
Multi-System Order Contribution: A record multi-system order from a top 20 global biopharma customer will contribute to system placements and revenue in Q4 2025, with related service revenue recognized in the first half of 2026. Consumable revenue from these systems is expected to ramp up in the second half of 2026.
MilliporeSigma Collaboration: MilliporeSigma has begun ordering Growth Direct Systems, with purchase commitments expected to become more meaningful in 2026. The collaboration is also expected to drive margin improvements starting in the second half of 2026.
Industry Trends and Tailwinds: The company is well-positioned to capitalize on industry trends such as increased automation in pharmaceutical manufacturing and investments in onshoring U.S. pharmaceutical production.
Consumables and Service Revenue Outlook: Q4 2025 consumable revenue is expected to step down sequentially to Q2 levels due to timing of customer orders. Service revenue is also expected to step down to roughly $2 million in Q4 due to timing of validation activities.
Operating Expenses and Cash Position: Full-year 2025 operating expenses are expected to be around $48 million, with the company ending the year with approximately $40 million in cash and investments.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Sean, in the last call, you indicated that you would be at the low end of the 21 to 25 system placement, and now you're going to be at least 27. Can you explain the guidance raise?
A:Sean explained that the increase in guidance is due to a large multi-system order that was not considered in the previous guidance. However, there are some offsets in Q4, such as lower-than-expected service revenue due to timing, which impacts the overall revenue guide.
Q:What does the geographical distribution of demand look like?
A:Rob stated that demand is generally consistent across North America, Europe, and Asia. The recent multi-system order reflects broad-based demand, and the company's value proposition is resonating globally. The win was not due to U.S. onshoring, which is expected to benefit in 2026 and beyond.
Q:What is the total size of the recent multi-system order, and how many will be delivered in Q4?
A:Rob did not disclose the exact order size or the number of systems to be delivered in Q4 but mentioned that it is a double-digit order.
Q:How many customers are looking to deploy systems globally across all three continents?
A:Rob mentioned that the company is striving for ubiquity and has historically seen customers purchase multi-system orders for global deployment. There are multiple multi-system orders in the pipeline, and the company plans to build on this momentum, particularly with the Merck Millipore relationship.
Q:Where is the company on the cost efficiency journey with Merck Millipore?
A:Sean explained that the company is in the process of testing and validating materials from Merck for consumables. Benefits from this activity are expected to start in the second half of next year.
Q:How is the company thinking about momentum against the current backdrop of scrutinized pharma biotech spending?
A:Rob stated that high ROI investments are still getting through despite tighter budgets. The company has been a beneficiary of this trend, and the recent multi-system order is an example of pharma investing in high ROI projects with strategic enterprise impact.
Q:When will onshoring have a significant impact?
A:Sean mentioned that onshoring is not expected to have a significant impact in 2026 but could start to feature more prominently in 2027 and beyond, depending on the pace of construction and expansion projects.
Q:How long does it take to validate and see consumable pull-through from large multi-system orders?
A:Sean explained that placements will impact Q4, with installations and validations expected in the first half of next year. Consumable pull-through is anticipated to ramp up in the second half of the year as systems move into GMP use.
Q:What traction is the company seeing in adjacent markets like personal care?
A:Rob stated that the company’s direct sales efforts are focused on global pharmaceutical and biopharma markets. Adjacent markets like personal care are being targeted through the collaboration with Merck MilliporeSigma, which has a larger and more globally spread sales force.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the total size of the recent multi-system order and the exact number of systems to be delivered in Q4. Additionally, while discussing onshoring, the response was somewhat vague about the timeline and potential impact, citing uneven progress and potential logjams in design and construction projects.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Act activity
Asia Pacific
Booth Pharma
Communications Rapid
Conference industry
Confirmation industry
Congress place
Day addition
Day facility
Direct Day
Direct System
Direct Systems
Direct customer
Direct placement
Direct platform
Germany event
Germany opportunity
Investor Relations
Jason Booth
MilliporeSigma Direct
ability
base
collaboration MilliporeSigma
colleague MilliporeSigma
contribution
customer Direct
demand
driver
momentum
network
record order
sale funnel
system order
week
RPID Transcript
Rapid Micro Biosystems, Inc. (RPID) Q1 2026 Earnings Call Transcript
Unknown5-13
The earnings call shows mixed signals: while there are positive developments like the Millipore JV expansion and potential margin improvements, there are also concerns such as increased net loss, operating expenses, and management's reluctance to provide clear guidance on key issues. The Q&A reveals cautious optimism but also highlights uncertainties. The lack of strong catalysts and the mixed guidance suggest a neutral impact on the stock price over the next two weeks.
Rapid Micro Biosystems, Inc. (RPID) Q4 2025 Earnings Call Transcript
Unknown3-12
The earnings call presents a mixed outlook. Positive aspects include increased consumable and recurring revenue, raised revenue guidance for 2025, and promising partnerships. However, concerns arise from inventory charges impacting margins, a widening net loss, and vague management responses in the Q&A. The lack of specific data on CDMO placements and Samsung orders adds uncertainty. While there are growth drivers, the immediate financial health and unclear guidance temper expectations, resulting in a neutral sentiment.
Rapid Micro Biosystems, Inc. (RPID) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-15
Rapid Micro Biosystems, Inc. (RPID) Q3 2025 Earnings Call Transcript
Positive11-7
The earnings call revealed positive signs such as a guidance raise due to a large multi-system order, consistent global demand, and improved service margins. Despite a net loss, operating expenses decreased, and cash reserves are strong. The MilliporeSigma partnership and high ROI investments further bolster the outlook. However, management's lack of clarity on some order specifics and onshoring timelines tempers enthusiasm. Overall, the positive factors outweigh the negatives, suggesting a stock price increase in the near term.
RPID Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
